Research and Development of AXL/EMT inhibitors

Offentlig prosjektsammendrag

BerGenBio is a clinical-stage oncology company advancing first-in-class, selective AXL kinase inhibitors as a potential cornerstone of combination therapy for multiple cancers. Blocking AXL is a novel approach in cancer therapy. AXL signalling plays a crucial role both in tumour cells where it promotes immune evasion, drug resistance and cancer spread, and in immune cells where it suppresses tumour recognition and cell-killing. Therefore, blocking AXL activity represents a novel approach to prevent cancer survival mechanisms and to improve the efficacy of chemotherapy, targeted therapy and immuno-oncology drugs.